Literature DB >> 25419235

Diabetic Retinopathy-Update on Prevention Techniques, Present Therapies, and New Leads.

Lauren M Marozas1, Patrice E Fort2.   

Abstract

Diabetic retinopathy is the major ocular complication associated with diabetes, and represents the leading cause of legal blindness in the working-age population of developed countries. Although classically diagnosed based on abnormalities of the retinal microvasculature, diabetic retinopathy is now widely recognized as a neurovascular disease. While all patients with diabetes are at increased risk for eye disease including diabetic retinopathy, proactive measures, and timely intervention can prevent or delay subsequent vision loss. Systemic management of diabetes by combined control of glycemia, blood pressure, and serum lipid levels remains the most important method of preventing diabetic retinopathy onset and progression. Once detected, surgical and medical interventions including photocoagulation, vitrectomy, and intravitral drug injection can help preserve vision. However, the need for improved detection methods and therapies that will allow earlier diagnosis and treatment remains apparent. This review summarizes current techniques for the prevention and intervention for diabetic retinopathy, and examines ongoing developments in the search for new endpoints and therapies as they apply to preventing vision loss associated with diabetes.

Entities:  

Keywords:  Diabetes; local intervention; new endpoints; novel therapies; prevention; retinopathy; systemic control; treatments

Year:  2014        PMID: 25419235      PMCID: PMC4239702          DOI: 10.17925/usor.2014.07.01.54

Source DB:  PubMed          Journal:  US Ophthalmic Rev        ISSN: 1756-1752


  109 in total

1.  Topical administration of nepafenac inhibits diabetes-induced retinal microvascular disease and underlying abnormalities of retinal metabolism and physiology.

Authors:  Timothy S Kern; Casey M Miller; Yunpeng Du; Ling Zheng; Susanne Mohr; Sherry L Ball; M Kim; Jeffrey A Jamison; David P Bingaman
Journal:  Diabetes       Date:  2007-02       Impact factor: 9.461

2.  ACE inhibition salvages the visual loss caused by diabetes.

Authors:  B V Bui; J A Armitage; M Tolcos; M E Cooper; A J Vingrys
Journal:  Diabetologia       Date:  2003-03-07       Impact factor: 10.122

3.  Quality of life and emotional change for middle-aged and elderly patients with diabetic retinopathy.

Authors:  Yao Yu; Lie Feng; Yi Shao; Ping Tu; He-Ping Wu; Xun Ding; Wei-Hua Xiao
Journal:  Int J Ophthalmol       Date:  2013-02-18       Impact factor: 1.779

4.  Triamcinolone acetonide inhibits p38MAPK activation and neuronal apoptosis in early diabetic retinopathy.

Authors:  X Zhang; D Lai; S Bao; B D Hambly; M C Gillies
Journal:  Curr Mol Med       Date:  2013-07       Impact factor: 2.222

5.  Resolution of diabetic macular edema after surgical removal of the posterior hyaloid and the inner limiting membrane.

Authors:  A Gandorfer; E M Messmer; M W Ulbig; A Kampik
Journal:  Retina       Date:  2000       Impact factor: 4.256

6.  Visual fields correlate better than visual acuity to severity of diabetic retinopathy.

Authors:  B Bengtsson; A Heijl; E Agardh
Journal:  Diabetologia       Date:  2005-11-01       Impact factor: 10.122

7.  Targeted deletion of Vegfa in adult mice induces vision loss.

Authors:  Toshihide Kurihara; Peter D Westenskow; Stephen Bravo; Edith Aguilar; Martin Friedlander
Journal:  J Clin Invest       Date:  2012-10-24       Impact factor: 14.808

8.  Activation of PKC-delta and SHP-1 by hyperglycemia causes vascular cell apoptosis and diabetic retinopathy.

Authors:  Pedro Geraldes; Junko Hiraoka-Yamamoto; Motonobu Matsumoto; Allen Clermont; Michael Leitges; Andre Marette; Lloyd P Aiello; Timothy S Kern; George L King
Journal:  Nat Med       Date:  2009-11-01       Impact factor: 53.440

9.  Protective role of pigment epithelium-derived factor (PEDF) in early phase of experimental diabetic retinopathy.

Authors:  Yumiko Yoshida; Sho-Ichi Yamagishi; Takanori Matsui; Yuko Jinnouchi; Kei Fukami; Tsutomu Imaizumi; Ryoji Yamakawa
Journal:  Diabetes Metab Res Rev       Date:  2009-10       Impact factor: 4.876

Review 10.  Neural degeneration in the retina of the streptozotocin-induced type 1 diabetes model.

Authors:  Yoko Ozawa; Toshihide Kurihara; Mariko Sasaki; Norimitsu Ban; Kenya Yuki; Shunsuke Kubota; Kazuo Tsubota
Journal:  Exp Diabetes Res       Date:  2011-11-17
View more
  4 in total

1.  Association of bilirubin and malondialdehyde levels with retinopathy in type 2 diabetes mellitus.

Authors:  Apoorva Dave; Pramila Kalra; B H Rakshitha Gowda; Malavika Krishnaswamy
Journal:  Indian J Endocrinol Metab       Date:  2015 May-Jun

2.  Overview of Ocular Anti-Vascular Endothelial Growth Factor Therapy in the Management of Diabetic Eye Complications.

Authors:  Oluwaranti Akiyode; Christine Tran
Journal:  Diabetes Spectr       Date:  2016-02

3.  Intravitreal injection of adenosine A2A receptor antagonist reduces neuroinflammation, vascular leakage and cell death in the retina of diabetic mice.

Authors:  Inês Dinis Aires; Maria Helena Madeira; Raquel Boia; Ana Catarina Rodrigues-Neves; Joana Margarida Martins; António Francisco Ambrósio; Ana Raquel Santiago
Journal:  Sci Rep       Date:  2019-11-20       Impact factor: 4.379

Review 4.  Diabetic Retinopathy: An Overview of Treatments.

Authors:  Bassirou A M Mounirou; Nouhou D Adam; Abba K H Yakoura; Mahamane S M Aminou; Yu T Liu; Li Y Tan
Journal:  Indian J Endocrinol Metab       Date:  2022-06-06
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.